Spoken Alpha
Cresco Labs Inc.
Cresco Labs Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $285.3M market cap.
Most recent earnings call: Q1 FY26 on May 8, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks CRLBF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CRLBF.
$ curl https://api.spokenalpha.com/v1/companies/CRLBFFAQ
Spoken Alpha indexes CRLBF's earnings call transcripts at https://spokenalpha.com/companies/CRLBF. Each call links to attributed speakers and parsed analyst Q&A. Cresco Labs Inc.'s own investor relations page is at https://investors.crescolabs.com/overview/default.aspx.
Cresco Labs Inc. (CRLBF) held its most recent earnings call on 2026-05-08, covering fiscal Q1 2026.
Cresco Labs Inc. (CRLBF) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.11 | $3.72 | -16.5% | -0.2% | +0.1% |
| Q4 FY2026 | $3.33 | $3.88 | -14.2% | +6.1% | +7.5% |
| Q3 FY2026 | $3.37 | $3.90 | -13.7% | +1.7% | -1.1% |
| Q2 FY2026 | $3.38 | $4.02 | -15.8% | -3.0% | -4.0% |
| Q1 FY2025 | $3.13 | $3.83 | -18.2% | +1.0% | +2.4% |
| Q4 FY2025 |
| $3.47 |
| $4.01 |
| -13.4% |
| +8.7% |
| +10.7% |
| Q3 FY2025 | $3.35 | $3.84 | -12.8% | -2.5% | -5.0% |
| Q2 FY2025 | $3.51 | $3.90 | -10.1% | +5.2% | +6.3% |
| Q1 FY2024 | $3.36 | $3.91 | -14.0% | +0.4% | -0.7% |
| Q4 FY2024 | $3.58 | $3.92 | -8.7% | +6.7% | +4.7% |